Phenotypes Associated with This Genotype

Genotype
MGI:5790497

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Tg(Upk2-cre)6Xrw/0; Tg(Upk2-HRAS*Q61L)5Xrw/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:234236 )

• mean survival of 231 days and median survival of 236 days

neoplasm

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors with progression to non-invasive papillary carcinomas (urothelial cell carcinoma)

• the number of proliferating cells within each tumor is increased compared to single conditional Ctnnb1^tm1Mmt homozygotes

• mice treated with a MEK1/2 inhibitor, PD184352, show tumor regression and reduction in proliferation

renal/urinary system

hematuria ( J:234236 )

• due to bladder tumors

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors with progression to non-invasive papillary carcinomas (urothelial cell carcinoma)

• the number of proliferating cells within each tumor is increased compared to single conditional Ctnnb1^tm1Mmt homozygotes

• mice treated with a MEK1/2 inhibitor, PD184352, show tumor regression and reduction in proliferation

homeostasis/metabolism

hematuria ( J:234236 )

• due to bladder tumors

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:234236